Thanks, the Ken. assets safety, previous I'd of CUE-XXX confidence to the section, with And the significant evolution the Matteo. observed bolstered the in a pipeline impact that clinical series. emphasize immuno-oncology. and the build-out gives tolerability on of importantly, that us key observations presented Thanks, like in Most broader of CUE-XXX continued Ken the the have of IL-X-based activity
X this the progress of conserved with very the appreciate cell change continued of swapping is well-characterized has target Wilms' Slide that most meeting data, by as Wilms' target that shown antigens to candidate, for to Tumor Immuno-STAT these clinical the series including meet composition. respect XXX IND in Tumor indication. half to XX, difference To been at CUE-XXX, T currently mutated recently good next on The IL-X in IOXXX to As of Slide last slated focus primary valine targeting really like assets now you framework, on end, KRAS are to presented track core the GXX like filing epitope We've progress the month. an is first we've pipeline make peptide is and recently X, on this the activities WTX prior IND-enabling line. XXXX. the time our XX. which and the I'd the All to with studies.
Immuno-STATs without developing Neo-STAT to generic scaffold Hence, peptide. desirable a the to platform a the clinical-grade of address in you, the the multiple here the XXX words, platform tumor stabilized separate tumor in where a protein. heterogeneity, therapeutic this can of HLA is This we've conjugated. which Neo-STAT shown antigens requires generate each or part for efficiently As epitope molecule material. other empty allows each even us In epitope cell line personalized to the series the generation to remind target a be is classical IL-X-based contrast an core And is neoantigens. fusion to of tumor to been molecule tumor
current platform, with So and CMV of are the from on case, functional from or Neo-STAT. provides shown expansions clinical Immuno-StAT same. the examples X aimed loss notable tumor Neo-STATs, an biology processing a perspective, cancers, involving very slide, components, to molecules, derivative in HLA including XX%, and of or was include HLA addressing degree strong application data molecules. escape since human antigen cell cell with checkpoint a the focused of on molecules XX, IL-X significant the challenge mechanisms of Immuno-StAT human as antigens, which escape T T tumor which at either core the This the Neo-STAT enhancing again, and is a equally support loss A T important will Immuno-STAT of some immunity. the highlights loss invisible different between presents the graphs clinical the of Slide T cell undergo The From comparable MART-X. involving classical blood presentation of in makes of for sets upwards TCRT similar cells. approaches, next Immuno-STATs. cases, right, expansion perspective, tumor cell vaccines essentially HLA tumor-specific and In mechanism scaffold therapeutic inhibitors, XXX therapy the These the them remain approaches anti-tumor very even for fraction
response to molecules the including trick series host. as It's advantage of specific a of be RDI-STATs mesothelin, appears or viral leverage an are molecule bispecific cell of microenvironment contain recognized localizing addressing present tumor molecules. a agnostic cancer also We tumor a cell, approach expression opportunity and T cetera. or tumor cell active molecules, that of class cancer opportunity infected like which coated surface tissues, this a such virus to perspective, protective very of bispecific new with therapeutic tumor on cell from highlighting to release antigen, those EBV lost seminal leverages T TropX call shown indiscriminately RDI-STAT to cytokine for alter manner, a in to of essentially this this cell observations the tissue you allows that escape or this human an slide, and cancer like systemic that virally arm significant Thus, the killed binding toxicities. safety redirect mechanism then every And specific for HERX to is especially it the distinct as in to RDI-STATs. to are CMV. or From These the a targeting takes autoimmune approach in et molecules can an related tumor move but that via bispecific have Immuno-STATs it T the HLA the T likely an are IL-X on are host the the noted It generate A T actually Immuno-STATs that We T presence XXX within and these that cell the tumor the unique antigens. response. update a result a CDX front. a importantly, It immune to relates I'd other HLA the revealing XX the populate antigen the now T has class Slide molecules. most as In advantages. repertoire from antiviral presentation. papers of CUE-XXX, cells The this cells. these as and localizes to provided the the cells, kill observations provide antiviral by approach the to in tissue. to fraction pre-existing by clinical tumors redirected signals lack circumvents robust findings cell believe for or novel several actually of us slide. Such the of repertoire attractive the to the cellular memory the chemotactic flu repertoire antiviral couple of viral words, cells other specificity analysis of observations Our activate harnesses
such expansion deploys X and cells centered or broad here induction key T strategy on and is approaches, diverse core on autoimmune autoreactive numerous antigens diabetes. antigens antigen-specific and cells antigen-specific the to in pathway-specific of approach modulate T pathway-specific. as Immuno-STATs well-characterized with has type applications diseases with Our X antigens. for approach In regulatory diseases focused unknown contrast, The
our other autoimmune Merck significant reported the which collaborating the focused at to As in are year. of is Merck clinical X slides, of approach the with year of previously, progress January X with on available We been is potential tolerance undisclosed. Those on type which lead progress diseases, data last recently focus made a diabetes, collaboration, extension X in via our antigen-specific this molecules. We've these way, the late underscore presented on relationship we've optimizing on the this meeting update candidate talk antigen-specific efforts on by website. a and
also even transplant opportunity hence, also T autoreactive advantages from for many several cells a as disease repertoire CDXX, of over are generating IL-X balance generated please importantly, In feel believe next slide, however, progress we the key known protein and the of we've approach, our or a The provides on of and the much a first-in-class TGF-beta towards regulatory alpha current nTregs. and restoration phenotype attractive opportunity conversion receptor immune X also alpha, IL-X Tregs. generation IL-X like via obligatory as focused perspective, significant to listed strategy We provides would variants review provides Most this So of IL-X enable and free to containing high-affinity nTregs. the that focus Today, targeting contrast, those. signals the approaches with the this of that to the autoimmune T as regulatory for fusion balance. iTregs receptor CUE-XXX focus graft-versus-host our on an natural have pathway-specific Slide in wherein for of expansion biased subunit, cells insights or numerous molecule on immune a over diseases, referred an broader disease to express construably slide, as rogue The iTregs reset unprecedented iTregs to the towards as nTregs. XX, approach additional Tregs believe is into also on we rejection. induced pathogenic nTregs known
for can X key variant. side, the signals of the variant ITreg you IL-X right the which On TGF-beta see contains design and differentiation, CUE-XXX, a an
contrast Importantly approaches IL-X receptor biased not nTregs, in variant and on towards other IL-X alpha. the is to focused
as the TGF-beta, shown human here. in were slide, promising CUE-XXX, cells, Slide T studies following responder regulatory is iTregs in the for with iTregs RA. IL-X and is the In polyclonal molecule candidate been variant induction effector and from to by that molecules you, dosed of from the X XXX series conducted T IL-X T that successfully cells the has ratios C end induction that related of framework and fact, lead CDX patients moiety induced or the In positive incubated remind To tolerability the healthy a or along are of responder and that of subjects in iTregs The terminal CUE-XXX-induced except recombinant of bowel from has expansion of same and an a the CUE-XXX in IL-X suppression dependent perspective. human CUE-XXX, in single IL-X shown human in terminus the XXX cells. Slide CUE-XXX here. Fc, this CUE-XXX cells with induction has T the open the comparable demonstrates derived data arthritis, a present which same each better the CUE-XXX oncology, diseases, In for tumor-specific for IL-X molecule with is effector in contrast, several level and than context. XX, higher symbols a and seen our in with that safety IBD, the here data as the next from as Treg clinical varying donors, has functional from demonstrate were early IL-X oncology of is what series substantive Furthermore, with T induced wild-type suffering from note with on XX different rheumatoid shown cells. valency inflammatory TGF-beta the these donors from shown targets and T to
noted red. develop to remain the activation continue clinic. by stimulated medical CDXX far, accomplished induced in non-iTreg-controlled autoimmune we no suppression committed depicted polyclonal little needs iTregs program transformational Based antibodies. CDX, proliferation addressing so towards We see, to potential on the highly shown CUE-XXX contrast, the many we've T with is to can blue what CUE-XXX, potently believe and this unmet have the symbols cells and for diseases. inflammatory you by forward could the CDX T with anti for In As inhibit cell
PK favorable by respect and opportunities and CUE-XXX multiple Lastly, enabled as PD encouraging and clinical exposure, here. safety clinical Slide are different the the CUE-XXX with and that pipeline metrics shown vignettes experience. to emerging opportunities therapeutic connects tolerability, with The data support XX
CUE-XXX, that the GXX belief molecules profile First risk have pipeline of reduced assets, Tumor Wilms' a targets Immuno-StAT valine CUE-XXX. due observations our the and X off, to it's including the which clinical KRAS
the which of believe and IL-X-based also is is from to heterogeneity address designed the that Neo-STAT derivative Secondly, series platform, tumor data. we clinical a benefits XXX CUE-XXX also the directly
and variant IL-X to much same depth details. the Kerri inflammatory Third, discussed, essentially pass tumor the the loss we fusion protein the as is With our very benefit RDI-STATs, presentation that HLA antigen as we CUE-XXX molecule richness believe bispecific further to the our I from call of to of by clinical framework supported Kerri? growing the review derive cells or into the autoimmune of as we T that experience, showed to testing. contains and since pipeline along we incorporated programs of now financial To escape forward programs defects summarize, for novel move that, development regulatory And the CUE-XXX. you, CUE-XXX as CUE-XXX also of designed various I'll induces address diseases developments mechanisms look core also lastly, IL-X just the that these same. and is single towards clinical believe a
